The HHS Advanced Research Projects Agency for Health (ARPA-H) is accepting submissions for the Fast Assessment of Solutions, Therapeutics, Pharmaceuticals, and SupplieS (FASTPASS) Innovative Solutions Opening, solicitation ARPA-H-SOL-26-160. FASTPASS is designed to create rapid, non-destructive tools that can verify pharmaceutical quality and safety through packaging at ports, warehouses, and other supply-chain nodes.
The program has two technical areas. TA1 SAMPLE focuses on advanced through-packaging sensing technologies, including spectrographic or other non-contact approaches. TA2 DETECT focuses on analytics and models that improve existing spectroscopic techniques and enable next-generation decision support. ARPA-H encourages teaming across non-contact spectroscopy, artificial intelligence and machine learning, pharmaceutical chemistry, and hardware engineering.
The required applicant-entry gate is the Solution Summary, due September 21, 2026 at 4:00 PM ET. Proposers that advance may submit a full proposal by November 10, 2026 at 4:00 PM ET. The controlling solicitation and attachments are maintained on SAM.gov under ARPA-H-SOL-26-160, and applicants should verify all current amendments, eligibility, award terms, budget and milestone requirements, intellectual-property provisions, registrations, and submission instructions there before proceeding.
Atlas Opportunity Score: 50/100. N9+ Fit: 12/100. This is a legitimate healthcare and pharmaceutical-supply-chain technology opportunity, but the published scope does not directly fund telehealth, remote physical examination, clinical services, or N9+ deployment. Dr. Miltie should not be advanced as a prime unless it can substantiate a credible contribution to the required sensing, analytics, pharmaceutical-screening, or implementation work.